Brookline Capital Markets Forecasts Moderna Q3 Earnings

Key Points

• Brookline Capital Markets raised its Moderna EPS forecasts, estimating a Q3 2026 loss of $1.24 per share versus its prior $1.30 estimate and maintaining a “Buy” rating. The firm still expects losses for 2026 and 2027, with profitability projected in 2028.
• Moderna’s latest quarterly results exceeded expectations, with an adjusted loss of $1.97 per share versus the $2.03 consensus and revenue of $145 million compared with estimates of $102.93 million. Revenue increased 2.1% year over year, though profitability metrics remained negative.
• Investor sentiment is mixed: Moderna shares opened at $154.27 after a reported 9.9% rise, while analysts hold a consensus “Hold” rating and an average price target of $80.53. Institutional investors and hedge funds own approximately 75.33% of the stock.

Moderna, Inc. (NASDAQ:MRNA - Free Report) - Investment analysts at Brookline Capital Markets increased their Q3 2026 earnings per share (EPS) estimates for Moderna in a report released on Monday, August 31st. Brookline Capital Markets analyst L. Cann now anticipates that the company will earn ($1.24) per share for the quarter, up from their previous forecast of ($1.30). Brookline Capital Markets currently has a "Buy" rating on the stock. The consensus estimate for Moderna's current full-year earnings is ($6.11) per share. Brookline Capital Markets also issued estimates for Moderna's Q4 2026 earnings at ($2.09) EPS, FY2026 earnings at ($6.46) EPS, FY2027 earnings at ($3.13) EPS and FY2028 earnings at $0.62 EPS.

Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings results on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, topping analysts' consensus estimates of ($2.03) by $0.06. The firm had revenue of $145.00 million during the quarter, compared to the consensus estimate of $102.93 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.The business's revenue was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($2.13) EPS.

Other research analysts have also recently issued reports about the company. Bradesco Corretora raised Moderna to an "outperform" rating in a research report on Friday. JPMorgan Chase & Co. increased their price objective on Moderna from $40.00 to $77.00 and gave the company an "underweight" rating in a report on Friday, August 21st. Weiss Ratings reissued a "sell (d-)" rating on shares of Moderna in a research note on Friday, June 12th. CLSA upgraded shares of Moderna to an "outperform" rating in a report on Friday. Finally, Morgan Stanley upped their price target on shares of Moderna from $39.00 to $89.00 and gave the stock an "equal weight" rating in a research report on Thursday, August 20th. Seven analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and an average price target of $80.53.

Moderna Stock Up 9.9%

Shares of MRNA stock opened at $154.27 on Wednesday. The firm's fifty day moving average price is $80.59 and its two-hundred day moving average price is $61.34. Moderna has a 1 year low of $22.28 and a 1 year high of $176.66. The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $61.59 billion, a P/E ratio of -19.31 and a beta of 1.09.

Hedge Funds Weigh In On Moderna

Institutional investors and hedge funds have recently modified their holdings of the business. AQR Capital Management LLC acquired a new stake in Moderna during the first quarter worth approximately $415,000. NewEdge Advisors LLC raised its position in shares of Moderna by 732.7% in the 1st quarter. NewEdge Advisors LLC now owns 11,575 shares of the company's stock valued at $328,000 after buying an additional 10,185 shares in the last quarter. United Services Automobile Association bought a new stake in shares of Moderna during the 1st quarter worth approximately $230,000. Focus Partners Wealth lifted its holdings in shares of Moderna by 58.7% during the 1st quarter. Focus Partners Wealth now owns 23,547 shares of the company's stock worth $668,000 after acquiring an additional 8,706 shares during the period. Finally, American Century Companies Inc. boosted its position in shares of Moderna by 5.2% during the 2nd quarter. American Century Companies Inc. now owns 48,859 shares of the company's stock worth $1,348,000 after acquiring an additional 2,410 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, President Stephen Hoge sold 53,336 shares of the company's stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $51.37, for a total value of $2,739,870.32. Following the transaction, the president owned 1,483,848 shares in the company, valued at approximately $76,225,271.76. This represents a 3.47% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Thyme Klinger sold 3,471 shares of the firm's stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $50.00, for a total transaction of $173,550.00. Following the sale, the insider owned 67,468 shares of the company's stock, valued at $3,373,400. This trade represents a 4.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 10.80% of the company's stock.

More Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Brookline raises near- and medium-term forecasts: Brookline Capital Markets maintained a “Buy” rating and raised its EPS estimates for Q3 2026 to ($1.24) from ($1.30), Q4 2026 to ($2.09) from ($2.16), FY2026 to ($6.46) from ($6.60), FY2027 to ($3.13) from ($3.24), and FY2028 to $0.62 from $0.53. The revisions suggest the analyst sees a somewhat faster path toward profitability, despite Moderna still being expected to report losses in 2026 and 2027. MarketBeat Moderna analyst estimates
• Positive Sentiment: Promising oncology results remain the key catalyst: Moderna and Merck reported positive late-stage results for their personalized melanoma vaccine, reinforcing the potential for Moderna to expand beyond COVID-19 vaccines and build a higher-value oncology business. Moderna oncology catalyst
• Positive Sentiment: Investor interest remains elevated: Options activity was unusually strong, with traders purchasing 106,605 call options—about 35% above typical call volume. This signals bullish positioning, although options activity can also increase volatility.
• Neutral Sentiment: Moderna will present at the Morgan Stanley Global Healthcare Conference on September 14 and the Bernstein Healthcare Forum on September 23, giving investors opportunities to hear updates on its pipeline, commercial outlook and financial plans. Moderna conference schedule
• Negative Sentiment: Competition in mRNA influenza vaccines is increasing: GSK advanced its rival mRNA flu vaccine into Phase III, creating a future competitive threat. However, Moderna’s recent FDA approval for the first seasonal mRNA flu vaccine means investors appear to view the development as validation of the market rather than an immediate commercial setback. GSK mRNA flu vaccine Phase III
• Negative Sentiment: Brookline modestly reduced its long-range EPS forecasts for FY2029 to $11.54 from $11.69 and FY2030 to $19.11 from $19.27. The cuts are small, but they temper the otherwise improving near-term outlook.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source